Vivo Capital Raises $750 Million for US-China Fund

Vivo Capital, a US-China healthcare investment company, closed its eighth fund at $750 million, which was two times Vivo's previous fund that raised $375 million three years ago. Vivo expects to invest in later development stage drug and device companies in the US and revenue-stage companies in China, with a focus on helping companies in both countries forge cross-border partnerships. Vivo, which has offices in Palo Alto, Shanghai, Beijing and Chengdu, now has assets under management of over $1.7 billion. More details.... Share this with colleagues: // //